Alnylam Pharmaceuticals | ALNY - Selling And Administration Expenses

Stock Price
305.54
Daily Change
-8.25 -2.63%
Monthly
-7.05%
Yearly
21.46%
Q2 Forecast
302.85

Alnylam Pharmaceuticals reported $285.06M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 146.73M 21.82M Dec/2025
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Amgen USD 1.94B 237M Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
Ionis Pharmaceuticals USD 130M 43.43M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Novartis USD 3.44B 132M Dec/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.75B 455M Dec/2025
Sarepta Therapeutics USD 105.38M 28.27M Dec/2025
Takeda JPY 282.78B 29.23B Dec/2025
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025
Xencor USD 17.04M 70.74M Dec/2025